Winifred W Prosise

USPTO Granted Patents = 9 (Patent Applications = 3)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 31(Granted Patents)

Location History:

Ramsey, NY (US) (2010)
Ramsey, NJ (US) (1999 - 2021)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

1 out of 55

Merck Sharp + Dohme B.v.

patents

4. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2021

Loading Chart...

9 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11014986 - Crystals of anti-human PD-1 monoclonal antibodies (2021-05-25),

2. 10556957 - Anti-CD27 antibodies (2020-02-11),

3. 9803010 - Crystalline anti-human IL-23p19 antibodies (2017-10-31),

4. 8048663 - Crystal of pregnane X receptor fused to steroid receptor coactivator-1 (2011-11-01),

5. 7785879 - Pregnane X receptor compositions, crystals and uses thereof (2010-08-31),

6. 7335758 - Catalytic domain of ADAM33 and methods of use thereof (2008-02-26),

7. 7208311 - Catalytic domain of ADAM33 and methods of use thereof (2007-04-24),

8. 6524589 - Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same (2003-02-25),

9. 5981167 - Surface plasmon resonance based enzymatic assay (1999-11-09),

Title: Winifred W. Prosise: Innovator in Monoclonal Antibody Research

Introduction

Winifred W. Prosise is a prominent inventor based in Ramsey, NJ (US). She has made significant contributions to the field of monoclonal antibodies, holding a total of 9 patents. Her work focuses on developing innovative solutions for cancer treatment and other diseases.

Latest Patents

Among her latest patents, Winifred has developed crystals of anti-human PD-1 monoclonal antibodies. These crystals, including those of pembrolizumab, are crucial for understanding the three-dimensional structure of these antibodies, which can lead to advancements in cancer therapies. Additionally, she has worked on anti-CD27 antibodies, which have potential applications in treating various diseases, including cancer and infectious diseases.

Career Highlights

Winifred has had a distinguished career, working with notable companies such as Schering Corporation and Merck Sharp & Dohme Corporation. Her expertise in antibody research has positioned her as a leader in the field, contributing to groundbreaking advancements in medical treatments.

Collaborations

Throughout her career, Winifred has collaborated with talented individuals, including Shahriar Shane Taremi and Paul Reichert. These partnerships have enhanced her research and led to significant innovations in monoclonal antibody development.

Conclusion

Winifred W. Prosise is a trailblazer in the field of monoclonal antibodies, with a strong portfolio of patents that reflect her dedication to advancing medical science. Her contributions continue to impact the treatment of cancer and other diseases, showcasing her role as a key innovator in the industry.

This text is generated by artificial intelligence and may not be accurate.